Related Experiment Videos
Parathyroid hormone, calcitonin, 1,25-dihydroxycholecalciferol, and basal bone resorption in the rat fetus
Calcified Tissue International
|January 1, 1983
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Nuclear retinoic acid receptor characterization in cultured human trophoblast cells: effect of retinoic acid on epidermal growth factor receptor expression.
Molecular and cellular endocrinology·1994
Effects of calcitonin on human trophoblastic cells in culture: absence of autocrine control.
Molecular and cellular endocrinology·1992
Effects of 1,25-dihydroxyvitamin D3 on in vitro lymphocyte reactions: arguments for a role at the maternofetal interface.
Gynecologic and obstetric investigation·1991
Effect of calcitriol on peripheral blood lymphocyte cytotoxicity.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·1991
Apatite c-axis Orientation Tracks Disc-Mediated Local Principal Stress Directions in the Human Lumbar Vertebra.
Calcified tissue international·2026
Methylmalonic Acid in Skeletal Aging and Osteoporosis: Linking Vitamin B12 Metabolism to Mitochondrial Dysfunction.
Calcified tissue international·2026
CD274 Knockout Promotes Bone Formation and Reduces Osteoclast Activity.
Calcified tissue international·2026
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026